Corcept Therapeutics Inc
CORT
Market Cap$7.35B
Close$
$202.59
192% upside
Current Fair Value
192% upsideUndervalued by 192% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.35 Billion |
|---|---|
| Enterprise Value | $7.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.35 |
| Beta | 0.2 |
| Outstanding Shares | 104,111,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 54.78 |
|---|---|
| PEG | -3779.4 |
| Price to Sales | 11.56 |
| Price to Book Ratio | 11.56 |
| Enterprise Value to Revenue | 10.2 |
| Enterprise Value to EBIT | 71.65 |
| Enterprise Value to Net Income | 55 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym? was the first drug approved...